A Featured NR From SH... "PharmaTher entered into an exclusive license agreement with the University of Arizona to develop and commercialize ketamine to treat Parkinson’s disease and movement disorders.
Study results from preclinical studies and case studies in Parkinson’s disease patients from the University of Arizona have shown that low-dose sub-anesthetic ketamine infusion indicates tolerability, safety and the potential of long-term therapeutic benefit to reduce levodopa-induced dyskinesia, improve on time, and reduce depression. 1-5
Parkinson’s disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson’s disease, although some drug combinations are used to treat the disease symptoms. The global Parkinson’s disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 2025 6 and it is estimated that the potential market opportunity for LID-PD to be over USD $3 billion in the U.S. alone."
Add Parkinson's disease/movement disorders to the Ketamine indication list...nice to see this off patent drug will soon be entering another critical clinical trial. Now we just need a low-dose Ketamine "thin strip". Perhaps COOL could benefit from the formation of an independent medical- scientific advisory board...could help guide & expedite their thin strip development & get these much needed drugs to market earlier & in a much more desirable/simpler form. Expecting more exciting news to come....JMO : ).